VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | CASTING: ocrelizumab safety profile in RRMS

Celia Oreja-Guevara, MD, PhD, University Hospital San Carlos, Madrid, Spain, discusses the results of the CASTING study (NCT02637856); a Phase IIIb study investigating the safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis (RRMS) who had previously failed first- or second-line treatment with other disease-modifying therapies (DMTs). The results were consistent with data from other trials. There was no difference between age groups or between patients from first- or second-line treatment; the primary side effects included an increase in infections, such as nasopharyngitis and infusion-related reactions. Past studies have focused on naïve patients, hence this data is a more accurate representation of the real-life safety of ocrelizumab in RRMS. This interview took place during the European Academy of Neurology 2021 congress.


C.Oreja-Guevara has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck, and Teva.